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Background:  Video-assisted thoracic surgery (VATS) lobectomy has been performed with increasing frequency over 
the last decade. However, there is still controversy as to its indications, safety, and feasibility. Especially regarding 
lung cancer surgery, it is not certain whether it can reduce local recurrences and improve overall survival. Materials 
and Methods: We retrospectively reviewed 1,067 cases of VATS lobectomy performed between 2003 and 2009, in-
cluding the indications, postoperative morbidity, mortality, recurrence, and survival rate. Results: One thousand and 
sixty seven patients underwent VATS lobectomy for the following indications: non-small cell lung cancer (NSCLC) 
(n=832), carcinoid tumors (n=12), metastatic lung cancer (n=48), and benign or other diseases (n=175). There were 
63 cases (5.9%) of conversion to open thoracotomy during VATS lobectomy. One hundred thirty one (15.7%) of 
the 832 NSCLC patients experienced pathologic upstaging postoperatively. The hospital mortality rate was 0.84% (9 
patients), and all of them died of acute respiratory distress syndrome. One hundred forty-nine patients (14.0%) ex-
perienced postoperative complications. The median follow-up was 22.9 months for patients with NSCLC. During fol-
low-up, 120 patients had a recurrence and 55 patients died. For patients with pathologic stage I, the overall sur-
vival rate and disease-free survival rate at 3 years was 92.2±1.5% and 86.2±1.9%, respectively. For patients with 
pathologic stage II disease, the overall survival rate and disease-free survival rate at 3 years was 79.2±6.5% and 
61.9±6.6%, respectively. Conclusion: Our results suggest that VATS lobectomy is a technically feasible and safe 
operation, which can be applied to various lung diseases. In patients with early-stage lung cancer, excellent surviv-
al can be also achieved.
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INTRODUCTION
    Throughout  the  last  decade,  the  number  of  video-assisted 
thoracic  surgeries  (VATS)  has  increased  rapidly  [1-3].  In  pa-
tients  with  early  stage  lung  cancer,  lobectomy  done  by  using 
a thoracoscope has been universalized. Technical stability has 
already been proven and the indication for thoracoscopy is di-
versifying [4-10]. However, some researchers have questioned 
t h e  s a f e t y  a n d  f e a s i b i l i t y  o f  t horacoscopy  performed  in  pa-
tients with lung cancer [11-14]. There is some debate regard-
ing  recurrence  and  survival  rates  after  thoracoscopic  lobec-
tomy  in  patients  with  early  stage  non-small  cell  lung  cancer Min Suk Choi, et al
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[8,13,15-19].  According  to  Rueth’s  [20]  retrospective  results 
in  a  study  about  thoracoscopic  lobectomies  have  done  since 
1994, post-surgical morbidity and inflammation were lower in 
patients  who  had  gone  through  thoracoscopic  lobectomy  than 
in patients who had gone through thoracotomic lobectomy. In 
addition,  there  was  no  difference  in  the  5-year  survival  rate 
when  comparing  the  results  of  thoracoscopic  lobectomy  with 
the  results  of  thoracotomic  lobectomy.  The  authors  of  the 
present study retrospectively analyzed 1,067 cases of thoraco-
scopic  lobectomy  and  their  indications,  conversion  rate  to 
thoracotomy during surgery, postsurgical complications, hospi-
tal  mortality  rate,  and  postsurgical  recurrence  and  survival 
r a t e  i n  o r d e r  t o  s u g g e s t  w a y s  t o  w i d e n  t h e  s u r g i c a l  a p p l i c a -
tion  of  the  thoracoscopic  lobectomy  in  the  future.
MATERIALS AND METHODS
    This  research  received  approval  from  the  clinic’s  institu-
tional  review  board.  1,067  patients  who  had  gone  through 
thoracoscopic  lobectomy  from  December  24,  2003,  to  Decem-
ber  31,  2009,  were  retrospectively  analyzed  based  on  their 
medical  records.  Data  regarding  age,  sex,  pre-surgical  diag-
nosis,  accompanying  disease,  date  of  surgery,  name  of  sur-
gery,  conversion  to  thoracotomy,  length  of  hospitalization, 
pathological  diagnosis,  presence  of  complications,  adjuvant 
chemotherapy,  follow-up  observation  period,  recurrence,  and 
survival  was  collected.
    Subjects  who  underwent  surgery  had  lesions  that  could  be 
excised  anatomically  and  showed  reduced  pulmonary  ventila-
tion  on  preoperative  pulmonary  function  tests.  The  subjects’ 
pulmonary  diseases  were  inflammatory  diseases  such  as  pul-
monary tuberculosis, empyema, congenital pulmonary disease, 
primary  lung  cancer,  metastatic  lung  cancer,  and  carcinoid 
tumor.  In  cases  with  benign  pulmonary  disease,  lobectomy 
was  performed  if  the  majority  of  the  pulmonary  lobe  was 
damaged,  or  segmentectomy  or  wedge  resection  could  not  be 
executed  due  to  the  proximity  of  the  lesion  to  the  central 
bronchus or vascular structures. However, thoracotomic lobec-
tomy was performed in cases of CT scan evidence of pleural 
calcification, severe calcification around pulmonary vessels, or 
thorax  deformation.  In  cases  of  non-small  cell  lung  cancer, 
thoracoscopic  lobectomy  was  executed  if  the  preoperative 
cancer  stage  was  stage  I  with  no  endobronchial  lesion,  if  the 
tumor  was  located  peripherally,  or  if  the  diameter  of  the  tu-
mor was less than 6 cm. In cases with a single metastasis to 
the  brain,  gamma  knife  surgery  was  performed  before  lobec-
tomy (5 cases). Pulmonary function testing, CT scanning, and 
PET CT scanning were done preoperatively. If non-small cell 
lung cancer was diagnosed pathologically before surgery, me-
diastinal  lymph  node  biopsies  were  performed  in  areas  2R, 
4R,  4L,  and  7  under  mediastinoscopy  even  if  there  was  no 
evidence  of  mediastinal  lymph  node  metastasis.  If  the  patient 
was  incapable  of  going  through  neoadjuvant  chemo-
radiotherapy  due  to  underlying  disease  or  old  age,  lobectomy 
was  executed  without  mediastinoscopy,  even  if  mediastinal 
lymph  node  metastasis  was  suspected.  Patients  with  no  diag-
nosis  of  preoperative  pathological  non-small  cell  lung  cancer 
underwent  thoracoscopic  wedge  resection,  the  frozen  section 
was  then  analyzed,  and  lobectomy  was  done  if  it  was  diag-
nosed  as  cancer.  The  excised  pulmonary  lobe  was  removed 
from  the  pleural  cavity  in  a  plastic  pouch  to  prevent  im-
plantation  of  cancer  cells  into  the  thoracic  wall  [19]. 
Mediastinal  lymph  node  dissections  were  performed  after  lo-
bectomy  in  all  patients  regardless  of  their  clinical  stage.  In 
c a s e s  i n v o l v i n g  t h e  r i g h t  p l e u r a l  c a v i t y ,  d i s s e c t i o n  o f  t h e  2 R ,  
3, 4R, 7, 8R, 9R, 10R, and 11R lymph nodes was performed. 
In cases involving the left pleural cavity, dissection of 4L, 5, 
6,  7,  8L,  9L,  10L,  and  11L  lymph  nodes  was  performed. 
Adjuvant chemotherapy or radiotherapy was done if the post-
operative  pathologic  stage  was  more  advanced  when  com-
pared  with  the  preoperative  clinical  stage.  CT  scans  were 
done  every  3  or  6  months  for  first  2  years  after  surgery  to 
check  for  recurrence.  After  2  years,  CT  scans  were  done  ev-
ery  6  months  or  more.  All  clinical  stages  or  pathological 
stages  of  non-small  cell  lung  cancer  reported  in  this  research 
were  retrospectively  applied  according  to  the  7
th  lung  cancer 
TNM staging [21] proposed by International Staging Commit-
tee  (ISC)  of  the  International  Association  for  the  Study  of 
Lung  Cancer  (IASLC).
    The  authors  of  this  research  performed  thoracoscopy  as 
follows.  After  general  anesthesia,  a  10-mm  access  port  for  a 
thoracoscope  was  made  in  the  seventh  or  eighth  intercostal 
space  of  the  mid-axillary  line  to  observe  the  pleural  cavity. 
Then, a 5 or 10 mm port was made in the seventh intercostal VATS Lobectomy
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Table 1. Pathologic diagnoses of 1,067 patients who underwent 
VATS lobectomy
Diagnosis Number
Primary  lung  cancer 842  (80.1%)
    Non-small  cell  lung  cancer 832  (78.1%)
      Adenocarcinoma 665
      Bronchioalveolar  carcinoma   31
      Squamous  cell  carcinoma   90
      Large  cell  carcinoma   28
   O t h e r s *    1 8
    Small  cell  lung  cancer     2
  O t h e r s
†   8
Carcinoid    12  (1.1%)
Pulmonary  metastasis   48  (4.5%)
Inflammatory  lung  disease 103  (9.6%)
    Pulmonary  TB  (MDR-TB)   24
  N T M  d i s e a s e   8
  A s p e r g i l l o m a  2 7
    Bronchiectasis   28
  O t h e r s  1 6
Congenital  lung  disease   25  (2.3%)
  C C A M   8
    Pulmonary  sequestration   14
  O t h e r s   3
Benign  lung  neoplasm   37  (3.5%)
    Sclerosing  hemangioma 　6
    Chondroid  hamartoma 　7
  L e i o m y o m a 　3
  O t h e r s  2 1
*=Sarcomatoid  carcinoma,  adenosquamous  cell  carcinoma,  etc.; 
†=Lymphoma,  sarcoma  etc.;  TB=Tuberculosis;  MDR-TB=Multi- 
drug  resistant  tuberculosis;  NTM=Nontuberculous  mycobacteria; 
CCAM=Congenital  cystic  adenomatoid  malformation.
Table 2. Reasons for conversion to thoracotomy
Lung  Benign  Total 
cancer disease number
Abnormal  anatomy  of  pulmonary  vessels 2 1 3
Bleeding 
From  a  pulmonary  artery  branch 19 1 20
　From  a  pulmonary  vein  branch 2 2
　F r o m  a  b r o n c h i a l  a r t e r y 1 1
　From  the  right  atrium 1 1
　Due  to  another  cause 1 1
Bronchial  tearing 2 2
Cancer  involvement  of  the  hilum 1 1
Cancer  involvement  of  the  LN 2 2
Direct  invasion  of
    Adjacent  lobe 2 2
  C h e s t  w a l l 1 1
  D i a p h r a g m 1 1
Broken-down  bronchial  stapler 1 1
Incomplete  fissure 3 3
Anthracofibrotic  or  calcified  LN 16 2 18
Pulmonary  artery  angioplasty 1 1
Pleural  adhesion 1 2 3
space of the posterior scapular line and a 4 or 5 cm working 
window  was  made  in  the  fifth  or  sixth  intercostal  space  of 
the  mid-clavicular  line.  Intercostal  space  was  not  widened  in 
all  cases.
    Descriptive statistics were used to collect the statistical data 
of  patients.  Continuous  variables  with  a  normal  distribution 
are  presented  with  averages  and  standard  deviations.  Discrete 
variables  are  presented  with  numb e r s  a n d  r a t i o s .  T h e  o v e r a l l  
survival  period  of  patients  who  were  still  alive  was  consid-
ered  to  be  the  period  from  the  date  of  surgery  to  either  the 
date  of  the  most  recent  visit  or  the  last  date  (March  17, 
2010)  all  living  patients  were  called.  If  the  patient  had  de-
ceased,  the  survival  period  was  considered  to  be  from  the 
date  of  surgery  to  the  date  of  death.  In  cases  of  relapse,  the 
disease  free  survival  period  was  considered  to  be  from  the 
date  of  surgery  to  the  date  of  relapse  diagnosis.  In  cases 
without  relapse,  the  disease-free  survival  period  was  set  from 
the  date  of  surgery  to  the  most  recent  visit  or  the  date  of 
death.  The  survival  curve  was  calculated  using  the 
Kaplan-Meier  method  using  PASW  Statistics  18  (SPSS  Inc., 
IBM, Chicago,  Illinois). The  log-rank  test was  used for com-
paring  the  survival  rates.
RESULTS
  From December 24, 2003 to December 31, 2009, 1,067 pa-
tients  (542  male,  525  female)  underwent  thoracoscopic 
lobectomy.  The  subjects’  diseases  included  non-small  cell 
cancer  (832),  carcinoid  tumor  (12),  metastatic  lung  cancer 
(48), and other diseases (175) (Table 1). The average age was 
56.9  years  (12∼86  years),  and  162  patients  (15.1%)  were 
over  70  years  old.  The  median  time  period  from  hospital-
ization to discharge was 6 days (2∼110 days). Most patients 
had  one  pulmonary  lobe  excised,  21  patients  went  through 
right upper or lower bilobectomy (1.97%, non-small cell can-Min Suk Choi, et al
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Table 3. Postoperative complications
      Complications Number
Prolonged  air  leak 62*
Postoperative  arrhythmia
† 24
Pneumothorax 16
ARDS/ALI 15
Chylothorax   9
Prolonged  effusion   6
Vocal  cord  palsy   6
Atelectasis
‡  4
Pneumonia   3
Postoperative  bleeding   3
Pulmonary  thromboembolism   3
Acute  myocardial  infarction   1
Empyema   1
Renal  infarction   1
Delirium   1
Diaphragmatic  hernia   1
Voiding  difficulty   1
Subcutaneous  emphysema   1
CVA   1
BPF   1
ARF   1
Sepsis   1
*=Of  those,  58  patients  required  chemical  pleurodesis; 
†=Atrial 
fibrillation  or  sinus  tachycardia; 
‡=Needed  bronchoscopic  toilet-
ing  or  reintubation;  ARDS=Acute  respiratory  distress  syndrome; 
ALI=Acute  lung  injury;  CVA=Cerebrovascular  accident;  BPF= 
Broncho-pleural  fistula;  ARF=Acute  renal  failure.
Table 4. Pathologic stages of the 832 patients who underwent 
VATS lobectomy for non-small-cell lung cancer (TNM staging sys-
tem for lung cancer, 7
th Edition)
     S t a g e N u m b e r  ( % )
IA 407  (48.9%)
IB 242  (29.1%)
IIA   91  (10.9%)
IIB   26  (3.1%)
IIIA   55  (6.6%)
IIIB     0 
IV   11  (1.3%)
Table 5. The pattern of recurrence of the 832 patients who un-
derwent VATS lobectomy for non-small-cell lung cancer according 
to pathologic stage
  Pathologic  stage Locoregional Distant Both
IA  (407) 10 10 5
IB  (242) 11 16 6
IIA  (91) 4 11 6
IIB  (26) 2 6 1
IIIA  (55) 9 12 4
IIIB  (0) −− −
IV  (11) 4 3 −
cer,  19  cases),  and  one  patient  had  a  pneumonectomy. 
Sixty-three  cases  (5.9%)  converted  to  thoracotomy  during 
thoracoscopic  surgery.  Common  causes  for  these  conversions 
were  hemorrhage  from  pulmonary  artery  branches  and  diffi-
culties  in  detaching  calcified  or  fibrous  lymph  nodes  (Table 
2).
    Nine  patients  (0.84%)  died  in  the  clinic  after  surgery.  All 
of  these  patients  underwent  lobectomy  because  of  non-small 
cell lung cancer  and  the  cause  of  death  was  the same  for  all 
cases,  acute  respiratory  distress  syndrome.  Five  patients 
among  them  had  diffuse  interstitial  pulmonary  disease. 
Complications  occurred  162  times  in  149  patients  (14.0%). 
The  most  common  complication  was  continuous  air  leakage 
(62 cases) (Table 3). The most common pathological stage of 
non-small  cell  lung  cancer  was  stage  I  with  649  cases 
(77.6%)  (Table  4).  The  average  follow-up  observation  period 
of  non-small  cell  lung  cancer  patients  was  22.9  months.  The 
number  of  patients  with  relapse  during  the  follow-up  ob-
servation  period  was  120,  and  55  of  them  died.  Among  pa-
tients  with  relapse,  40  patients  had  local  relapse,  58  patients 
had  remote  relapse,  and  22  patients  had  both  local  and  re-
mote  relapses  (Table  5).  After  surgery,  166  patients  under-
went  adjuvant  chemotherapy  (106  patients),  radiation  therapy 
(19  patients),  or  chemoradiotherapy  (41  patients).  The  overall 
1-year  and  3-year  survival  rates  for  all  non-small  cell  lung 
cancer  patients  were  96.6±7%  and  89.5±1.6%,  respectively. 
The  disease-free  1-year  and  3-year  survival  rates  were 
91.8±1.0%  and  77.0±2.1%,  respectively.  The  1-year  and 
3-year  overall  survival  rates  of  407  patients  in  pathological 
stage  IA  were  98.6±6%  and  94.1±1.8%,  respectively.  The 
disease-free  1-year  and  3-year  survival  rates  were  97.5±8% 
and  89.7±2 . 2 % ,  r e s p e c t i v e l y .  T w o  h u n d r e d  a n d  f o r t y - t w o  p a -
tients  in  pathological  stage  IB  showed  overall  1-year  and 
3-year  survival  rates  of  94.3±1.5%,  and  89.1±2.5%, 
respectively.  The  disease-free  survival  rates  were  91.6±1.9% VATS Lobectomy
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Fig. 1. Overall survival and disease-free survival of patients who underwent VATS lobectomy for non-small cell lung cancer.
Fig. 2. Overall survival and disease-free survival of the pathologically upstaged 122 patients among 769 clinical stage I patients.
and  80.3±3 . 7 %  f o r  1  a n d  3  y e a r s ,  r e s p e c t i v e l y .  T h e r e  w e r e  
117  cases  where  the  pathological  stage  was  stage  II. 
Postoperative  overall  survival  rates  at  1  and  3  years  were 
96.2±1.9% and 79.2±6.5%, respectively. The disease-free sur-
v i v a l  r a t e s  a t  1  y e a r  a n d  3  y e a r s  w e r e  8 1 . 4 ±3.9%  and 
61.9±6.6%.  Fifty-five  cases  were  in  pathological  stage  III. 
Postoperative  overall  survival  rates  at  1  and  3  years  were 
94.2±3.3% and 83.1±7.2%, respectively. The disease-free sur-
vival r ates at 1  an d 3  y ears w ere 79 .0±5.9% and 21.4±9.6%, 
respectively  (Fig.  1).
    Among  the  832  patients  with  non-small  cell  lung  cancer, 
769  patients  were  in  clinical  stage  I,  of  which  122  (15.9%) 
showed increased pathological stage after  surgery. The 1-year 
and 3-year overall survival rates of these patients were 95.7± 
1.9% and 82.5±5.0%, respectively. The 1-year and 3-year dis-
ease-free  survival  rates  were  85.2±3.4%  and  45.9±6.8%,  re-
spectively  (Fig.  2).  The  most  common  cause  of  the  patho-
logic  upstaging  was  pathological  diagnosis  showing  local  or 
mediastinal  lymph  node  metastasis  while  no  lymph  node 
metastasis in the clinical stage. Sixty-four patients out of 813 
showed  a  preoperative  clinical  stage  of  N0  and  a  post-
operative stage of N1. Their 1-year and 3-year overall surviv-
al  rates  were  95.0±  2.8%  and  74.8±8.7%,  respectively.  The 
1-year  and  3-year  disease-free  survival  rates  were  83.6±5.0% 
and 53.8±9.3%, respectively. Forty-eight patients showed pre-
operative  clinical  stage  N0  and  postoperative  pathological 
stage  N2.  Their  1-year  and  3-year  overall  survival  rates  were 
93.3±3% and 84.6±7.2%, respectively. Th e 1- year  an d 3 -y ear Min Suk Choi, et al
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Fig. 3. Overall survival and disease-free survival of the pathologic N1 (64) and N2 (48) patients among 813 clinical N0 patients.
disease-free  survival  rates  were  81.0±6.1%  and  21.4±9.7%, 
respectively  (Fig.  3).
DISCUSSION
    The  application  of  VATS  has  been  expanding  from  dis-
eases such as benign pleural disease, lung disease, and media-
stinal  disease  [3]  to  lung  cancer  and  esophageal  cancer  [22]. 
The  range  of  pulmonary  resections  has  also  been  expanding, 
currently  including  pulmonary  wedge  resection,  segmentec-
tomy,  lobectomy,  bilobectomy,  and  even  pneumectomy  [1]. 
McKenna  et  al.  [23]  reported  on  the  largest  number  of  thor-
acoscopic lobectomy cases in a single institute. Their thoraco-
scopic  indications  were  primary  lung  cancer,  lymphoma, 
metastatic  lung  cancer,  or  benign  pulmonary  disease,  which 
were  similar  to  the  author’s  indications. 
    A  low  number  of  postoperative  complications  and  a  low 
hospital  mortality  rate  have  been  reported  in  various  articles. 
Hospital mortality rate after thoracotomic lobectomy has been 
found  to  be  similar  to  that  of  thoracoscopic  lobectomy, 
whereas  postoperative  complications  were  less  common  in 
thoracoscopic  lobectomy  [4,20,24].  These  results  are  similar 
to  the  results  of  our  study  in  complication  occurrence  rate 
(14.0%,  162  cases)  and  hospital  mortality  rate  (0.84%). 
Among  postoperative  complications,  continuous  air  leakage 
was  the  most  common.  In  order  to  minimize  leakage,  a  sta-
pler was used for isolation rather than electrocautery or blunt 
dissection when severe adhesion was present in the interlobar 
fissure.  Then,  denuded  visceral  pleura  was  covered  with  ab-
sorbable felt or applied with glue to reduce air leakage. There 
are  numerous  risk  factors  affecting  hospital  mortality.  In  this 
study, 5 out of the 9 patients who died in the clinic had dif-
fuse  interstitial  lung  disease.  This  implies  that  patients  with 
diffuse  interstitial  lung  disease  must  cautiously  decide  wheth-
er  to  undergo  a  lobectomy,  which  may  compromise  lung 
function  after  surgery.  Since  FEV1  levels  are  often  normal 
based  on  pulmonary  function  testing,  diffusing  capacity 
(DLco)  must  be  measured  and  operation  should  be  avoided 
w h e n  D L c o  l e v e l s  a r e  l o w  [ 2 5 ] .  I n  a d d i t i o n ,  V A T S  i s  l e s s  
painful  than  thoracotomy  [26]  and  has  a  shorter  hospital-
ization  period.
    There  have  been  numerous  reports  regarding  the  fact  that 
thoracoscopic  lobectomy  is  not  oncologically  different  from 
thoracotomic lobectomy. Rueth and Andrade [20] showed that 
there  were  no  oncological  differences  between  thoracoscopic 
and  thoracotomic  lobectomy  by  analyzing  research  articles 
about  thoracoscopic  lobectomy  from  1994  to  present 
[8,17,18].  Yan  et  al.  [27]  showed  that  the  5-year  disease-free 
survival  rate  of  thoracoscopic  lobectomy  was  significantly 
higher  than  that  of  thoracotomic  lobectomy  (p=0.03).
    Sugi et al. [17] and Watanabe et al. [28] showed that there 
was  no  difference  in  the  number  of  collected  lymph  nodes, 
survival  rate,  and  recurrence  when  comparing  thoracoscopic 
mediastinal  lymph  node  dissection  and  thoracotomic  media-
stinal  lymph  node  dissection.  Common  causes  for  conversion 
from  thoracoscopic  surgery  to  thoracotomic  surgery  were VATS Lobectomy
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hemorrhage  in  pulmonary  artery  branches  and  difficulty  in 
detaching  a  calcified  or  fiberized  lymph  node.  To  reduce  the 
conversion  rate,  preoperative  CT  should  be  analyzed  thor-
oughly to check for the calcification or fibrosis of lymph no-
des  along  with  thickening. 
  O n the o th er h and,  ther e are diff er ent view s abo ut th e f ea-
sibility  of  the  thoracoscopic  lobectomy  for  lung  cancer. 
Opponents  of  insist  that  thoracoscopic  lobectomy  results  in 
lower survival rate and higher  relapse rate. Thoracoscopic lo-
bectomy  may  result  in  more  manipulation  of  the  lung,  caus-
ing  cancer  cells  to  disseminate  through  the  pulmonary  vein 
[13].  In  addition,  excisions  with  a  stapler  may  leave  cancer 
cells  at  the  resection  margin,  mediastinal  lymph  node  dis-
section  may  be  insufficient,  and  cancer  cells  may  be  dis-
seminated while removing the specimen out of the body [19]. 
In the author’s institute, the pulmonary vein was detached be-
fore  the  pulmonary  artery,  if  possible,  the  resection  margin 
was  checked first with the  naked  eye,  and  the resection mar-
gin  went  through  a  frozen  section  reading  when  there  was  a 
possibility  of  cancer  cells  remaining.  Mediastinal  lymph  no-
des were completely dissected in all cases. There has been no 
established  definition  of  complete  lymph  node  dissection. 
However, the authors defined complete lymph node dissection 
to  mean  where  no  lymph  node  or  fatty  tissue  remained.  To 
prevent  damage  to  the  nerves  or  thoracic  duct,  an  ultrasonic 
cutter  (Harmonic  ACE
TM,  Ethicon  Endo-Surgery  Inc.,  Cincin-
nati,  OH)  was  used.  When  removing  the  specimen  after  lo-
bectomy, the specimen was placed in a plastic bag to prevent 
dissemination  of  cancer  cells. 
    The  pathological  stage  I  patients’  3-year  disease-free  sur-
vival  rate  was  86.2±1.9%,  whereas  pathological  stage  II  pa-
tients’  3-year  disease-free  survival  rate  was  61.9±6.6%. 
However,  it  is  too  early  to  affirm  that  the  postoperative  re-
lapse rate of stage I non-small cell lung cancer is low or that 
stages greater than II have greater postoperative relapse rates. 
In  order  to  draw  a  more  accurate  conclusion  on  the  relapse 
and  survival  rates  of  patients  treated  with  thoracoscopic  lo-
bectomy  for  early  non-small  cell  lung  cancer,  long-term  fol-
low-up  observation  is  needed.  In  the  previous  articles,  an 
analysis of the 5-year overall survival rate after thoracoscopic 
lobectomy  for  early  stage  non-small  cell  lung  cancer  was 
conducted, whereas most of the previous studies have not re-
ported  specifics  about  5-year  disease-free  survival  rates 
[15,18,20,23].  Yamamoto  et  al.  [29]  recently  reported  the  pa-
tients’ 5-year survival and disease-free survival rate and cate-
gorized  them  by  each  stage.
    Some recent studies have focused on whether patients who 
are  diagnosed  with  clinical  stage  I  and  end  up  with  patho-
logical  stage  II  or  worse  after  thoracoscopic  lobectomy  show 
lower  survival  and  greater  relapse  rates  than  patients  treated 
with thoracotomic lobectomy. In the present study, it was not 
possible  to  draw  conclusions  on  this  topic,  since  there  were 
no comparisons made with thoracotomic lobectomy. However, 
according  to  the  Kim  et  al’s  [30]  results  in  the  past  4  years, 
and  reports  by  Watanabe  et  al.  [28]  over  9  years,  there  has 
been  no  difference  in  prognosis,  and  we  have  concluded  that 
conversion  to  thoracotomic  surgery  is  not  necessary  even  if 
N2  lymph  node  metastasis  is  observed  during  surgery.  In  or-
der  to  minimize  pathologic  upstaging,  efforts  to  improve  the 
accuracy  of  preoperative  diagnosis  are  necessary.
    The consistency of the research results from our clinic was 
maintained by using the same medical team to perform oper-
ations  with  identical  indications  and  criteria  (lymph  node  bi-
opsy  and  mediastinal  lymph  node  dissection  under  media-
stinoscopy).  Also,  with  a  relatively  abundant  amount  of  data 
(1,067  cases),  results  such  as  low  morbidity,  low  hospital 
mortality,  and  low  conversion  rate  are  acceptable.
    In  the  future,  the  number  of  patients  with  early  stage  non- 
small cell lung cancer with an indication of thoracoscopic lo-
bectomy  will  increase.  As  diagnostic  techniques  advance,  the 
number of patients with early stage lung cancer is increasing, 
adenocarcinoma  is  becoming  more  common  than  squamous 
cell  carcinoma.  Adenocarcinoma  is  usually  located  periph-
erally, which facilitates a thoracoscopic approach. In addition, 
the  number  of  female  patients  with  the  disease  is  increasing, 
in  which  the  aesthetic  benefits  of  thoracoscopic  surgery  are 
more  preferable.  As  more  thoracoscopic  lobectomy  experi-
ences  are  documented  in  the  future,  thoracoscopic  lobectomy 
could be applied to the patients in stage II lung cancer or pa-
tients  with  endobronchial  cancer  needing  a  sleeve  lobectomy. 
But  more  prospective  studies  are  necessary  to  recognize  it  as 
a  feasible  method  of  treatment.
    Lastly,  there  are  several  limitations  in  this  research.  First, 
data  was  analyzed  retrospectively  and  there  were  no  compar-Min Suk Choi, et al
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isons  made  with  thoracotomic  lobectomy.  Second,  in  spite  of 
the  fact  that  all  operations  were  performed  in  a  single  in-
stitute  with  identical  indications,  it  is  possible  that  the  sur-
geons  performed  thoracoscopic  surgery  in  cases  with  better 
expected  prognosis.  Prospective  randomized  controlled  trials 
in  the  future  may  produce  more  conclusive  results.  Finally, 
since  the  number  of  patients  within  a  year  increased  more 
than  50%  when  compared  with  previous  research  [31],  the 
overall  follow-up  observation  period  was  short.  Therefore,  a 
longer  follow-up  observation  period  of  thoracoscopic  lobec-
t o m y  f o r  e a r l y  s t a g e  n o n - s m all  cell  lung  cancer  would  be 
necessary  to  verify  long-term  results.
CONCLUSION
    Based  on  our  6  years  of  experience,  thoracoscopic  lobec-
tomy is a safe and useful method for treating various pulmo-
nary  diseases  including  early  non-small  cell  lung  cancer, 
without  a  high  complication  occurrence  rate  or  hospital  mor-
tality  rate.  In  addition,  an  excellent  survival  rate  was  ob-
served  in  patients  with  early  non-small  cell  lung  cancer. 
However,  depending  on  the  stage  of  the  disease,  continued 
collection  of  data  may  be  necessary  to  observe  long-term 
results.
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